Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference

Dateline City: WHITEHOUSE STATION, N.J. Initiates rolling submission of U.S. Biologics License Application (BLA) for MK-3475, the company’s anti-PD-1 immunotherapy; expects to complete application in first half of 2014. Prepares for 2014 regulatory actions for V503, vintafolide (EU), vorapaxar, NOXAFIL IV, vaniprevir (Japan) and AIT-Grass and AIT-Ragweed; anticipates filing odanacatib, suvorexant. Evaluates the role of Merck’s Animal Health and Consumer Care businesses in the company’s strategy for long-term value creation; expects conclusions to be reached and action, if any, to be taken in 2014. Divests assets, including a portion of the U.S. ophthalmics business, SAPHRIS U.S. marketing rights and Sirna Therapeutics, Inc. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today will report on the strategic and operating actions it is taking to drive short- and long-term growth, including sharpening its focus in core markets and therapeutic areas, advancing its innovative pipeline and unlocking the value in non-core areas of its business. Language: English Contact: ...
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news